| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
B Activation Pathway
1 Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas and 2 Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia
Requests for reprints: Bharat B. Aggarwal, Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-794-1817; Fax: 713-794-1613. E-mail: aggarwal{at}mdanderson.org
Recent reports have indicated that honokiol can induce apoptosis, suppress tumor growth, and inhibit angiogenesis. In this report, we found that honokiol potentiated the apoptosis induced by tumor necrosis factor (TNF) and chemotherapeutic agents, suppressed TNF-induced tumor cell invasion, and inhibited RANKL-induced osteoclastogenesis, all of which are known to require nuclear factor-
B (NF-B) activation. Honokiol suppressed NF-B activation induced by a variety of inflammatory stimuli, and this suppression was not cell type specific. Further studies showed that honokiol blocked TNF-induced phosphorylation, ubiquitination, and degradation of IB
through the inhibition of activation of IB kinase and of Akt. This led to suppression of the phosphorylation and nuclear translocation of p65 and NF-B-dependent reporter gene expression. Magnolol, a honokiol isomer, was equally active. The expression of NF-B-regulated gene products involved in antiapoptosis (IAP1, IAP2, Bcl-xL, Bcl-2, cFLIP, TRAF1, and survivin), proliferation (cyclin D1, cyclooxygenase-2, and c-myc), invasion (matrix metalloproteinase-9 and intercellular adhesion molecule-1), and angiogenesis (vascular endothelial growth factor) were also down-regulated by honokiol. Honokiol also down-regulated NF-B activation in in vivo mouse dorsal skin model. Thus, overall, our results indicate that NF-B and NF-B-regulated gene expression inhibited by honokiol enhances apoptosis and suppresses osteoclastogenesis and invasion. (Mol Cancer Res 2006;4(9):621–33)
This article has been cited by other articles:
|
|
 |
|
  A. Garcia, Y. Zheng, C. Zhao, A. Toschi, J. Fan, N. Shraibman, H. A. Brown, D. Bar-Sagi, D. A. Foster, and J. L. Arbiser Honokiol Suppresses Survival Signals Mediated by Ras-Dependent Phospholipase D Activity in Human Cancer Cells Clin. Cancer Res., July 1, 2008; 14(13): 4267 - 4274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-R. Hahm, J. A. Arlotti, S. W. Marynowski, and S. V. Singh Honokiol, a Constituent of Oriental Medicinal Herb Magnolia officinalis, Inhibits Growth of PC-3 Xenografts In vivo in Association with Apoptosis Induction Clin. Cancer Res., February 15, 2008; 14(4): 1248 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-R. Hahm and S. V. Singh Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity Mol. Cancer Ther., October 1, 2007; 6(10): 2686 - 2695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Ahn, G. Sethi, T.-H. Chao, S. T. C. Neuteboom, M. M. Chaturvedi, M. A. Palladino, A. Younes, and B. B. Aggarwal Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-{kappa}B regulated gene products Blood, October 1, 2007; 110(7): 2286 - 2295. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
